Outlook and conclusion
The global CRAMS market is expected to grow further, to approximately US$85 billion by 2012. Many companies will lose patent protection for their block-busters in the next few years. This has compelled them to look to alternatives, such as entering into the generic field and cost efficiencies. As a result of this, the outsourcing of activities like the manufacturing of intermediates and APIs to lowcost destinations such as India is gaining momentum amongst pharmaceutical multinationals as they focus on their core R&D and brand-building business.
The Indian CRAMS market is estimated to reach US$7.6 billion by 2012. With a high and increasing number of USFDA approved plants in India, cost advantage and skilled manpower, ...
Get Contract Research and Manufacturing Services (CRAMS) in India now with the O’Reilly learning platform.
O’Reilly members experience books, live events, courses curated by job role, and more from O’Reilly and nearly 200 top publishers.
